• Cogent Biosciences signed a commercial supply agreement with Hovione on Sept. 1, 2026, covering bezuclastinib spray-dried dispersion and tablets.
• Purchases set through rolling quarterly forecasts, with a near-term binding portion; Cogent must source minimum requirement shares from Hovione.
• Initial term of five years, followed by automatic two-year renewals; termination rights include breach, force majeure, insolvency, regulatory or legal changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-380194), on September 02, 2026, and is solely responsible for the information contained therein.